{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:16:35Z","timestamp":1783383395616,"version":"3.54.6"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,7]]},"abstract":"<jats:p>This scientific commentary refers to \u2018Propionic acid in multiple sclerosis: a phase 2b, double blind, randomized placebo-controlled trial\u2019, by Moser et al. (https:\/\/doi.org\/10.1093\/brain\/awag099).<\/jats:p>","DOI":"10.1093\/brain\/awag192","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T01:50:33Z","timestamp":1783302633000},"page":"2187-2188","source":"Crossref","is-referenced-by-count":0,"title":["Propionic acid and neurofilament light chain in multiple sclerosis"],"prefix":"10.1093","volume":"149","author":[{"given":"Sofia","family":"Sandgren","sequence":"first","affiliation":[{"name":"Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Department of Neurology, University Hospital and University of Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Biomedicine, University Hospital and University of Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University Hospital and University of Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6172-801X","authenticated-orcid":false,"given":"David","family":"Leppert","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Department of Neurology, University Hospital and University of Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Biomedicine, University Hospital and University of Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University Hospital and University of Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-8892","authenticated-orcid":false,"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Department of Neurology, University Hospital and University of Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Biomedicine, University Hospital and University of Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University Hospital and University of Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"2026070619573966800_awag192-B1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/acn3.795","article-title":"Blood neurofilament light as a potential endpoint in phase 2 studies in MS","volume":"6","author":"Sormani","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"2026070619573966800_awag192-B2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol"},{"key":"2026070619573966800_awag192-B3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders\u2014Towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"2026070619573966800_awag192-B4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.bbalip.2010.07.007","article-title":"Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms","volume":"1801","author":"Al-Lahham","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"2026070619573966800_awag192-B5","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.immuni.2015.09.007","article-title":"Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine","volume":"43","author":"Haghikia","year":"2015","journal-title":"Immunity"},{"key":"2026070619573966800_awag192-B6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41586-018-0119-x","article-title":"Microglial control of astrocytes in response to microbial metabolites","volume":"557","author":"Rothhammer","year":"2018","journal-title":"Nature"},{"key":"2026070619573966800_awag192-B7","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.cell.2020.02.035","article-title":"Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism","volume":"180","author":"Duscha","year":"2020","journal-title":"Cell"},{"key":"2026070619573966800_awag192-B8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41577-024-01014-8","article-title":"Short-chain fatty acids: Linking diet, the microbiome and immunity","volume":"24","author":"Mann","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"2026070619573966800_awag192-B9","doi-asserted-by":"crossref","first-page":"fcae182","DOI":"10.1093\/braincomms\/fcae182","article-title":"Propionic acid promotes neurite recovery in damaged multiple sclerosis neurons","volume":"6","author":"Gisevius","year":"2024","journal-title":"Brain Commun"},{"key":"2026070619573966800_awag192-B10","first-page":"2286","article-title":"Propionic acid in multiple sclerosis: A phase 2b, double-blind, randomized placebo-controlled trial","volume":"149","author":"Moser","year":"2026","journal-title":"Brain"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awag192\/68541299\/awag192.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/7\/2187\/68541299\/awag192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/7\/2187\/68541299\/awag192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:57:56Z","timestamp":1783382276000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/149\/7\/2187\/8709766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":10,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,6]]},"published-print":{"date-parts":[[2026,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awag192","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]}}}